Alligator and Aptevo report positive interim data in Phase 1 trial of ALG.APV-527 for solid tumor treatment.

Alligator Bioscience and Aptevo Therapeutics announce positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 for solid tumor treatments expressing tumor antigen 5T4. The trial is over 50% enrolled, with preliminary results showing ALG.APV-527 drug exposure and biological activity. Early signs of clinical activity are observed in heavily pretreated patients, and dose-escalation trial data is expected by 2H 2024.

March 07, 2024
4 Articles